IPO registrations (S-1, F-1) · Registrants
Anbio Biotechnology
- SEC CIK
- 1982708 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2024-12-31, last 2025-02-10; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2025-02-19; declared effective 2025-02-18
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances 2835
- Incorporated in
- E9
- Business address
- FRIEDRICH-EBERT-ANLAGE 49, Frankfurt Am Main, 2M 60308
- Ticker
- NNNN (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- Anbio Biotechnology on the corporate pages
Offering terms
- Final price
- $5.00 per share (424B4 filed 2025-02-19, an initial public offering)
- Shares sold
- 1,600,000
- Gross proceeds
- $8,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol NNNN
- Lead underwriters
- AC Sunshine Securities LLC
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Anbio Biotechnology EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2024-12-31 | F-1 | F-1 (foreign registration) | Anbio Biotechnology | 0001213900-24-114129 ↗ |
| 2025-01-10 | F-1/A | F-1/A (amendment) | Anbio Biotechnology | 0001213900-25-002551 ↗ |
| 2025-01-24 | F-1/A | F-1/A (amendment) | Anbio Biotechnology | 0001213900-25-006373 ↗ |
| 2025-02-10 | F-1/A | F-1/A (amendment) | Anbio Biotechnology | 0001213900-25-011623 ↗ |
| 2025-02-18 | EFFECT | EFFECT (declared effective) | Anbio Biotechnology | 9999999995-25-000497 ↗ |
| 2025-02-19 | 424B4 | 424B4 (final prospectus) | Anbio Biotechnology | 0001213900-25-015001 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-10 | F-1/A | registration statement | 500,000,000 | - | 0 | primary document; shares headline | document ↗ | |||
| 2025-02-19 | 424B4 | final prospectus | $5.00 | 1,600,000 | $8,000,000 | Nasdaq NNNN | 1 | primary document; price sentence, shares headline, proceeds table, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Hartzler Nancy | Director | 1 | 2026 | ||
| LAU MICHAEL | Officer | CEO | 1 | 2026 | |
| Song Suki | Officer | CFO | 1 | 2026 | |
| TIAN CHRIS | Officer | CBO | 1 | 2026 | |
| XU CANY | Director | 1 | 2026 | ||
| HSU DAVID H | Director | 1 | 2026 | ||
| ZHANG MICHAEL W.C | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Anbio Biotechnology | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry In Vitro & In Vivo Diagnostic Substances, 2M first:
- Asep Medical Holdings Inc. A1
- DNA Testing Centers Corp A6
- NYMOX PHARMACEUTICAL CORP A8
- MABCURE INC. B9
- ANSYS DIAGNOSTICS INC CA
- Monogram Biosciences, Inc. CA
- ARGONAUT TECHNOLOGIES INC CA
- GENENCOR INTERNATIONAL INC CA
- Intuity Medical, Inc. CA
- Global Wholehealth Partners Corp CA
In other datasets, the same topic (Health) in 2M:
- Form D issuer: ATAI Life Sciences AG (Form D private offerings)
Interests: In Vitro & In Vivo Diagnostic Substances · Health